A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals.
Looking at options history for Regeneron Pharmaceuticals REGN we detected 10 strange trades.
If we consider the specifics of each trade, it is accurate to state that 10% of the investors opened trades with bullish expectations and 90% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $153,162 and 6, calls, for a total amount of $387,650.
What's The Price Target?
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $700.0 to $900.0 for Regeneron Pharmaceuticals over the last 3 months.
Volume & Open Interest Development
In terms of liquidity and interest, the mean open interest for Regeneron Pharmaceuticals options trades today is 147.75 with a total volume of 172.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Regeneron Pharmaceuticals's big money trades within a strike price range of $700.0 to $900.0 over the last 30 days.
Regeneron Pharmaceuticals Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| REGN | CALL | TRADE | BEARISH | 09/15/23 | $820.00 | $188.9K | 20 | 102 |
| REGN | CALL | TRADE | BEARISH | 01/19/24 | $770.00 | $62.3K | 492 | 11 |
| REGN | PUT | SWEEP | BEARISH | 01/17/25 | $700.00 | $55.2K | 334 | 0 |
| REGN | CALL | SWEEP | BEARISH | 01/19/24 | $900.00 | $48.8K | 198 | 20 |
| REGN | PUT | TRADE | BEARISH | 08/25/23 | $815.00 | $38.8K | 0 | 24 |
Where Is Regeneron Pharmaceuticals Standing Right Now?
- With a volume of 147,779, the price of REGN is down -0.02% at $806.82.
- RSI indicators hint that the underlying stock may be overbought.
- Next earnings are expected to be released in 80 days.
What The Experts Say On Regeneron Pharmaceuticals:
- Guggenheim has decided to maintain their Buy rating on Regeneron Pharmaceuticals, which currently sits at a price target of $900.
- Oppenheimer has decided to maintain their Outperform rating on Regeneron Pharmaceuticals, which currently sits at a price target of $950.
- RBC Capital has decided to maintain their Sector Perform rating on Regeneron Pharmaceuticals, which currently sits at a price target of $820.
- Barclays has decided to maintain their Overweight rating on Regeneron Pharmaceuticals, which currently sits at a price target of $900.
- Morgan Stanley has decided to maintain their Overweight rating on Regeneron Pharmaceuticals, which currently sits at a price target of $912.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Regeneron Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
